Angina (Angina Pectoris)-Pipeline Review, H1 2017

Angina (Angina Pectoris)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9222IDB
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Angina (Angina Pectoris)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris)-Pipeline Review, H1 2017, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 3, 1, 1 and 1 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Angina (Angina Pectoris)-Overview

Angina (Angina Pectoris)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Angina (Angina Pectoris)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Angina (Angina Pectoris)-Companies Involved in Therapeutics Development

Amgen Inc

Angionetics Inc

Juventas Therapeutics Inc

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

TSH Biopharm Corporation Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Angina (Angina Pectoris)-Drug Profiles

alferminogene tadenovec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranolazine ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-407899-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XC-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Angina (Angina Pectoris)-Dormant Projects

Angina (Angina Pectoris)-Discontinued Products

Angina (Angina Pectoris)-Product Development Milestones

Featured News & Press Releases

Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study

Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program

Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial

Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Angina (Angina Pectoris), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Angina (Angina Pectoris)-Pipeline by Amgen Inc, H1 2017

Angina (Angina Pectoris)-Pipeline by Angionetics Inc, H1 2017

Angina (Angina Pectoris)-Pipeline by Juventas Therapeutics Inc, H1 2017

Angina (Angina Pectoris)-Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Angina (Angina Pectoris)-Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Angina (Angina Pectoris)-Pipeline by Sanofi, H1 2017

Angina (Angina Pectoris)-Pipeline by Shire Plc, H1 2017

Angina (Angina Pectoris)-Pipeline by TSH Biopharm Corporation Ltd, H1 2017

Angina (Angina Pectoris)-Pipeline by ViroMed Co Ltd, H1 2017

Angina (Angina Pectoris)-Pipeline by XyloCor Therapeutics Inc, H1 2017

Angina (Angina Pectoris)-Dormant Projects, H1 2017

Angina (Angina Pectoris)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Angina (Angina Pectoris)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc, Angionetics Inc, Juventas Therapeutics Inc, Kuhnil Pharmaceutical Co Ltd, Lee's Pharmaceutical Holdings Ltd, Sanofi, Shire Plc, TSH Biopharm Corporation Ltd, ViroMed Co Ltd, XyloCor Therapeutics Inc

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com